The purpose of this observational study is to follow Endometrial Cancer patients through standard of care treatment of their Endometrial Cancer and collect biomedical and patient reported outcomes data.

The purpose of this study is to test if a hormonal drug Letrozole used either by itself or by adding it to the usual combination of chemotherapy drugs can help lower the chance of your ovarian or peritoneal cancer from growing or spreading.

Have you been diagnosed with uterine pre-cancer (endometrial intraepithelial neoplasia, EIN) ? if so, you may be able to participate in a research study to see if giving metformin and megestrol acetate together may decrease the growth of endometrial intraepithelial neoplasia in the uterus better than megestrol alone.

Have you been diagnosed with Metastatic Castration-Resistant Prostate Cancer. If so, you may be able to take part in a research study looking at the safety of giving Docetaxel vs Docetaxel and Radium-223 to patients.

Have you been diagnosed with uterine cancer called endometrial serous carcinoma or carcinosarcoma? If so, you may be able to take part in a research study to test if adding a drug or drugs that target HER2 proteins in addition to the usual combination of chemotherapy drugs could prevent your cancer from returning or shrink your cancer.

Do you have known or suspected lung and/or head and neck cancer? Are you scheduled for a tumor biopsy? If so, you may be able to participate in a research registry aimed at learning more about lung and head/neck cancer.

Are you receiving initial treatment for non-small cell lung cancer or invasive squamous cell carcinoma of the head and neck and want to participate in research that aims to improve treatment and care of future patients with the same diagnosis? If so, you may be able to participate in a study for an investigational blood test to predict whether your cancer will come back.

In this study, we want to learn more about the safety and effectiveness of using a personalized vaccine with a drug called pembrolizumab for the treatment of non‐small cell lung cancer (NSCLC) and squamous cell cancer of the head and neck (SCCHN).

People with SCLC are usually treated with a combination of drugs that are approved by the Food and Drug Administration (FDA). However, these drugs may no longer be working in controlling your cancer or may not be a good treatment option for you. This study uses an investigational combination of drugs, trilaciclib and lurbinectedin. The purpose of this study is to test whether trilaciclib helps minimize the side effects of lurbinectedin and therefore improve the safety of lurbinectedin for the treatment of small cell lung cancer (SCLC).

This is a research study to investigate how collecting information about treatment-related side effects directly from patients can help manage the side effects associated with certain oral chemotherapies in patients with metastatic renal cell carcinoma.